MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 01/02/23
Want to Collect a Dividend Every Month Next Year? Buy These 3 High-Yielding StocksThe Motley Fool • 12/29/22
Merck, Sichuan Kelun enter cancer collaboration, with milestone payments up to $9.3 billionMarket Watch • 12/22/22
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of CancerBusiness Wire • 12/22/22
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate CancerBusiness Wire • 12/21/22
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic UroPRNewsWire • 12/20/22
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial CancerBusiness Wire • 12/20/22